I did not like the results of this study and found it quite depressing.
Patients with primary Sjögren's syndrome are prone to develop serious complications over the long term, despite the presumption that this is a relatively benign autoimmune disease, a 25-year review found.
For instance, fully half developed an additional autoimmune disease such as cutaneous lupus, and one in every 10 was diagnosed with non-Hodgkin's lymphoma, according to Esha Abrol, BSc, of University College London.
The study was of only152 patients but they had been studied since 1986. There were other important facts that came out of this study as well:
- one quarter of the patients had nervous system involvement and peripheral neuropathy
- 18.5% of patients had died at an average age of 72, which is 10 years earlier than the average life expectancy of a woman un the UK
- the most common disease was non- Hodgkin's lymphoma
I am not sure what can be done about this except to enjoy life while we have it and have regular check ups by a specialist in Sjogren's Syndrome.
Do you feel that you have a good specialist who understands all this?
Do you feel that you have a good specialist who understands all this?
Read the full report from Medpage. Maybe we should be printing it out and taking it to our specialists.
Hello.
ReplyDeleteSBH Diagnostics, a Massachusetts CLIA Lab is offering pilot testing of Sjogren’s Samples from whole blood.
SBH Diagnostics, Inc. has a novel blood test for Sjogren’s syndrome. The SBH Diagnostic test is called EASy-Sjogren’s (Early, Accurate and Sensitive). Up to now there has been no single test that can be used to make a definitive diagnosis of Sjögren’s Syndrome in its early stages. The EASy-Sjogren’s Test is designed to provide results within 72 hours of receipt of a blood sample.
The EASy-Sjogren’s test is based upon quantifying altered Post Translational Modifications (PTMs - phosphorylation’s) of selected proteins from patients with Sjogren's syndrome. SBH Diagnostics will develop and commercialize the Sjogren’s syndrome test under CLIA regulation and will offer it to clinicians, and pharmaceutical and biotechnology companies that desire more accurate Sjögren’s Syndrome diagnosis, clinical trials management, and pre-clinical therapeutic development.
For further information please contact:
Marvin A. Collin
VP Business Development
SBH Diagnostics
macollin@sbhdiagnostics.com
That is a depressing study. I hope they used a sicker-than-average sample of patients.
ReplyDelete